Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease

被引:11
|
作者
Ueceyler, Nurcan [1 ,3 ]
Schroeter, Nils [1 ,3 ]
Kafke, Waldemar [1 ,3 ]
Kramer, Daniela [1 ,3 ]
Wanner, Christoph [2 ,3 ]
Weidemann, Frank [2 ,3 ,4 ]
Sommer, Claudia [1 ,3 ]
机构
[1] Univ Wurzburg, Dept Neurol, Wurzburg, Germany
[2] Univ Wurzburg, Dept Internal Med, Wurzburg, Germany
[3] Univ Wurzburg, Wurzburg Fabry Ctr Interdisciplinary Therapy FAZI, Wurzburg, Germany
[4] Katharinen Hosp Unna, Innere Klin 2, Obere Husemannstr 2, D-59423 Unna, Germany
来源
PLOS ONE | 2016年 / 11卷 / 11期
关键词
ENZYME REPLACEMENT THERAPY; PAIN SYMPTOM INVENTORY; SMALL FIBER NEUROPATHY; AGALSIDASE-BETA; DIAGNOSIS; NEPHROPATHY; BIOPSIES; EFFICACY; SAFETY; TRIAL;
D O I
10.1371/journal.pone.0166484
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background The X-chromosomally linked life-limiting Fabry disease (FD) is associated with deposits of the sphingolipid globotriaosylceramide 3 (Gb3) in various tissues. Skin is easily accessible and may be used as an additional diagnostic and follow-up medium. Our aims were to visualize skin Gb3 deposits in FD patients applying immunofluorescence and to determine if cutaneous Gb3 load correlates with disease severity. Methods At our Fabry Center for Interdisciplinary Therapy we enrolled 84 patients with FD and 27 healthy controls. All subjects underwent 5-mm skin punch biopsy at the lateral lower leg and the back. Skin samples were processed for immunohistochemistry using antibodies against CD77 (i.e. Gb3). Cutaneous Gb3 deposition was quantified in a blinded manner and correlated to clinical data. Results We found that Gb3 load was higher in distal skin of male FD patients compared to healthy controls (p<0.05). Men (p<0.01) and women (p<0.05) with a classic FD phenotype had higher distal skin Gb3 load than healthy controls. Men with advanced disease as reflected by impaired renal function, and men and women with small fiber neuropathy had more Gb3 deposits in distal skin samples than males with normal renal function (p<0.05) and without small fiber neuropathy. Gb3 deposits were not different between patients with and without enzyme replacement therapy. Conclusions Immunofluorescence on minimally invasive skin punch biopsies may be useful as a tool for assessment and follow-up in FD patients.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies
    Thurberg, BL
    Byers, HR
    Granter, SR
    Phelps, RG
    Gordon, RE
    O'Callaghan, M
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (04) : 900 - 908
  • [32] Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment
    Mauer, Michael
    Sokolovskiy, Alexey
    Barth, Jay A.
    Castelli, Jeffrey P.
    Williams, Hadis N.
    Benjamin, Elfrida R.
    Najafian, Behzad
    JOURNAL OF MEDICAL GENETICS, 2017, 54 (11) : 781 - 786
  • [33] Increased urinary CD80 excretion and podocyturia in Fabry disease
    Trimarchi, H.
    Canzonieri, R.
    Schiel, A.
    Costales-Collaguazo, C.
    Politei, J.
    Stern, A.
    Paulero, M.
    Rengel, T.
    Andrews, J.
    Forrester, M.
    Lombi, M.
    Pomeranz, V.
    Iriarte, R.
    Muryan, A.
    Zotta, E.
    Sanchez-Nino, M. D.
    Ortiz, A.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [34] Increased urinary CD80 excretion and podocyturia in Fabry disease
    H. Trimarchi
    R. Canzonieri
    A. Schiel
    C. Costales-Collaguazo
    J. Politei
    A. Stern
    M. Paulero
    T. Rengel
    J. Andrews
    M. Forrester
    M. Lombi
    V. Pomeranz
    R. Iriarte
    A. Muryan
    E. Zotta
    M. D. Sanchez-Niño
    A. Ortiz
    Journal of Translational Medicine, 14
  • [35] A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease
    Schiffmann, Raphael
    Swift, Caren
    Wang, Xuan
    Blankenship, Derek
    Ries, Markus
    JOURNAL OF INHERITED METABOLIC DISEASE, 2015, 38 (06) : 1129 - 1136
  • [36] Control of proteinuria with increased doses of agalsidase alfa in a patient with Fabry disease with atypical genotype-phenotype expression
    Paliouras, Christos
    Aperis, Georgios
    Lamprianou, Foteini
    Ntetskas, Giorgos
    Roufas, Konstantinos
    Alivanis, Polichronis
    NEFROLOGIA, 2015, 35 (06): : 578 - 581
  • [37] Increased expression of Trpv1 in peripheral terminals mediates thermal nociception in Fabry disease mouse model
    Lakoma, Jarmila
    Rimondini, Roberto
    Montiel, Antonio Ferrer
    Donadio, Vincenzo
    Liguori, Rocco
    Caprini, Marco
    MOLECULAR PAIN, 2016, 12 : 1 - 16
  • [38] Ceria-Zirconia nanoparticles reduce intracellular globotriaosylceramide accumulation and attenuate kidney injury by enhancing the autophagy flux in cellular and animal models of Fabry disease
    An, Jong Hun
    Hong, Sang-Eun
    Yu, Seong-Lan
    Kang, Jaeku
    Park, Chang Gyo
    Lee, Hoi Young
    Lee, Sung-Ki
    Lee, Dong Chul
    Park, Hwan-Woo
    Hwang, Won-Min
    Yun, Sung-Ro
    Park, Yohan
    Park, Moon Hyang
    Yoon, Kuk Ro
    Yoon, Se-Hee
    JOURNAL OF NANOBIOTECHNOLOGY, 2022, 20 (01)
  • [39] Cardiac involvement in Anderson-Fabry disease. The role of advanced echocardiography
    Spinelli, Letizia
    Bianco, Antonio
    Riccio, Eleonora
    Pisani, Antonio
    Iaccarino, Guido
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
  • [40] Significant improvement in Fabry disease podocytopathy after 3 years of treatment with agalsidase beta
    Ito, Shuichi
    Ogura, Masao
    Kamei, Koichi
    Matsuoka, Kentaro
    Warnock, David G.
    PEDIATRIC NEPHROLOGY, 2016, 31 (08) : 1369 - 1373